New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:49 EDTXON, OGENOragenics advancing towards identification of lead antibiotic clinical candidate
Oragenics (OGEN) announced that through its Exclusive Channel Collaboration with Intrexon Corporation (XON), it has produced and analyzed a large number of new potential analogs generated from its Mutacin 1140 antibiotic program platform, and advanced several promising compounds for further evaluation. These compounds will serve as the basis for selecting a lead drug candidate for clinical development later this year. The triaged analogs were selected from hundreds of variants generated using genetic engineering at Intrexon. Dr. John N. Bonfiglio, CEO of Oragenics, remarked, "The compounds we have selected for final evaluation align with our goal of identifying the first lead compound this year. We plan on meeting with the FDA later this year to discuss the IND enabling activities necessary to submit an IND application by mid-2015. Intrexon’s synthetic biology expertise in collaboration with our scientists has enabled generation of a large library of new potential MU1140 analogs with chemical and biological properties that differentiate from native MU1140. We remain very optimistic that these new lantibiotics will become useful in the fight against certain drug-resistant bacteria.”
News For OGEN;XON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2015
19:10 EDTOGENOn The Fly: After Hours Movers
Subscribe for More Information
16:30 EDTOGENOragenics reports positive In Vivo antibiotic efficacy data in animal study
Subscribe for More Information
July 27, 2015
07:56 EDTXONIntrexon price target raised to $70 from $55 at Wunderlich
Subscribe for More Information
July 21, 2015
08:06 EDTXONIntrexon names Jack Bobo as Chief Communications Officer
Subscribe for More Information
July 20, 2015
08:10 EDTXONFibrocell Science, Intrexon file IND for FCX-007
Fibrocell Science (FCSC) and Intrexon (XON) announced the submission of an Investigational New Drug, or IND, Application with the FDA for FCX-007, Fibrocell's lead orphan gene-therapy drug candidate for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use